anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Bupivacaine
Trial phase: Phase 2
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 56
Group description: These are not two separate drugs, but a mixture of Bupivacaine and Clonidine.

0.25% Bupivacaine + Clonidine : Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine
Eligibility criteria:
Inclusion Criteria:

age 1-18 years
tympanomastoid surgery (cochlear implant, mastoidectomy, cholesteatoma surgery)
ASA I, II
informed consent and assent obtained

Exclusion Criteria:

allergic to local anesthestic
taking chronic aspirin or Ibuprofen therapy
ASA IV
history of clinically important renal, hepatic, respiratory, cardiac, or neurological conditions
Patients who have cardiovascular surgery other than an atrial septal defect or a ventricular septal defect, or who have undergone complete corrective intracardiac repair of congenital heart disease.
Informed consent not obtained
Patients expected to receive dexamethasone or ondansetron intra-operative
Intervention: Buspirone
Trial phase: Not Applicable
ATC code: N05BE01
SMILES: O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 9
Group description: Subjects will be maintained on buspirone.

Buspirone: Subjects will be maintained on oral buspirone (administered 3 times daily) or placebo for 6 days each during the study in random order. These subjects will be the same as those who are maintained on placebo (i.e., the study uses a within-subjects design).
Eligibility criteria:
Inclusion Criteria:

Recent cocaine use

Exclusion Criteria:

Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians deem clinically significant
Current or past histories of substance abuse or dependence that are deemed by the study physicians to interfere with study completion
History of serious physical disease, current physical disease, impaired cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study participation will be excluded from participation
Females not currently using effective birth control
Contraindications to cocaine or buspirone
Intervention: Varenicline
Trial phase: Phase 4
ATC code: N07BA03 | S01XA28
SMILES: c1cnc2cc3c(cc2n1)C1CNCC3C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 45
Group description: 1 mg of varenicline twice per day for 12 weeks.

Varenicline: 1 mg of varenicline twice per day for 12 weeks and brief behavioral counseling
Eligibility criteria:
Inclusion Criteria:

Subjects must be ≥ 18 years of age;
smokes 5 to 10 CPD for at least 6 months;
express interest in quitting smoking;
indicate ability to complete all study visits; and
provide written informed consent to participate in the study.
Subject is a female subject of non-childbearing potential or a female subject of childbearing potential - who is using contraceptives and has a negative pregnancy test result;
Subject is in good health as determined by the investigator;
Subject has the ability to participate fully in all aspects of the study and keep scheduled appointments.

Exclusion Criteria:

An active medical condition such as unstable angina, myocardial infarction, or coronary angioplasty within the past 3 months or an untreated cardiac dysrhythmia;
History of renal failure;
Cancer [excluding non-melanoma skin cancer] not in remission;
Psychosis or bipolar disorder;
Current unstable or untreated moderate or severe depression as assessed by the CES-D;
have, as defined by the C-SSRS (Columbia-Suicide Severity Rating Scale), current non-specific suicidal thoughts, or have a lifetime history of a suicidal attempt (defined as "potentially self-injurious act committed with at least some wish to die, as a result of act.");

Substance dependence other than nicotine, defined as:

a. Patient has a recent history (past month) of heavy alcohol consumption as defined by NIAAA: i. Men: More than 4 drinks on any day or 14 per week ii. Women: More than 3 drinks on any day or 7 per week. b. Use of cocaine, heroin, club drugs (i.e., MDMA/"ecstasy"), methamphetamine, or hallucinogens (e.g., LSD) at any time during the past month.

c. Use of marijuana on a weekly basis for the past month

An allergy to varenicline;
Current use of a behavioral or pharmacologic tobacco dependence treatment and unwilling or unable to discontinue use;
Another member of their household already participating in this study; and
Current treatment with another investigational drug (within 30 days of study entry).
Has an unstable medical condition;
Subject has untreated hypertension or baseline systolic blood pressure > 180 or diastolic > 100;
Women of child-bearing potential, or who are pregnant, lactating or likely to become pregnant during the trial and are unwilling to use an acceptable form of contraception during the medication phase will also be excluded. All female subjects of childbearing potential must have a negative pregnancy test and must agree to use approved contraception during participation in the study.
Intervention: Clozapine
Trial phase: Phase 4
ATC code: N05AH02
SMILES: CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 23
Group description: The blinded CLOZ will be titrated on a recommended standard schedule, supervised by a study physician (or other prescriber) who can make the necessary adjustments to account for symptom control and tolerability. The titration is recommended to begin at 12.5 mg and then increase while the open-label base antipsychotic is tapered with a recommended goal of decreasing the base antipsychotic by 25% each week. If clinically tolerated, the target dose of CLOZ is 400 mg/day.

Clozapine: Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day
Eligibility criteria:
Inclusion Criteria:

Clinical diagnosis of schizophrenia
Clinical diagnosis of a cannabis use disorder (abuse or dependence)

Exclusion Criteria:

Pregnant,trying to become pregnant or nursing
History of a seizure disorder
Current treatment with clozapine or risperidone
Contraindication to treatment with clozapine or risperidone
Intervention: Risperidone
Trial phase: Phase 4
ATC code: N05AX08
SMILES: Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 24
Group description: The blinded RISP will also be titrated in the first weeks, using a titration schedule, with a target dose of 4 mg/day, while the open label base antipsychotic is tapered in a similar fashion.

Risperidone: Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day
Eligibility criteria:
Inclusion Criteria:

Clinical diagnosis of schizophrenia
Clinical diagnosis of a cannabis use disorder (abuse or dependence)

Exclusion Criteria:

Pregnant,trying to become pregnant or nursing
History of a seizure disorder
Current treatment with clozapine or risperidone
Contraindication to treatment with clozapine or risperidone
Intervention: Fostamatinib
Trial phase: Phase 2
ATC code: B02BX09
SMILES: COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 115
Group description: Fostamatinib 100 mg qd
Eligibility criteria:
Inclusion Criteria:

Provision of informed consent prior to any study-specific procedures.
Patients who have successfully completed study D4300C00008 and whose disease is adequately controlled, in the opinion of the Investigator.

Exclusion Criteria:

Premature withdrawal from study D4300C00008 or in the opinion of the Investigator the patient's disease is not adequately controlled on current treatment.
Development of any of the withdrawal criteria from study D4300C00008
Females who are pregnant or breast feeding
Any other clinically significant disease or disorder, which in the opinion of the Investigator might put the patient at risk due to participation in the study, or may influence the results of the study
Intervention: Methadone Hydrochloride
Trial phase: Not Applicable
SMILES: CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 34
Group description: Patients in oral medicine group will be treated by active vitamin D and other general treatments according to the suggestions in KDIGO guidelines.

Active vitamin D: CKD patients suffered from sHPT with 1-3 enlarged gland(s) and without indication of parathyroidectomy will be randomized to oral medicine therapy group or ultrasonic ablation therapy group. Patients in oral medicine group will be treated by active vitamin D and other general treatments, such as dietary phosphate restriction and phosphate binders, according to the suggestions in KDIGO guidelines.
Eligibility criteria:
Inclusion Criteria:

Patients with age between 18 - 75 years.
Patients with parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan.
CKD patients in stage 5, with elevated intact parathyroid hormone (iPTH) levels > 800pg/mL.
CKD patients have been followed up more than 6 months.

Exclusion Criteria:

Primary or Tertiary Hyperparathyroidism (hyperparathyroidism after kidney transplantation).
Patient who underwent total parathyroidectomy and without enlarged parathyroid gland(s).
Known history of parathyroid or other neoplasias in the neck region.
History of neck irradiation.
Major surgery of neck in the last 3 months or other major surgery projected in the subsequent 4 months.
Pregnant or lactating woman.
Patient receiving drugs such as phenobarbital, phenytoin, rifampicin, sucralfate, steroids, flecainide, thioridazine, or most tricyclic antidepressants which could affect vitamin D metabolism.
Treatment with vitamin D derivatives, cinacalcet or other calcimimetics within the past 6 months.
Patients who are currently participating in another clinical trial.
The expected live time is less than 1 year.
Patients suffered from acute myocardial infraction, acute congestive heart failure, or stroke in last 6 months.
Patients whose concurrent illnesses, disability, or geographical residence would hamper attendance at required study visit.
Intervention: CID 12303048
Trial phase: Not Applicable
ATC code: S03AA04
SMILES: NC(=NCCCCCCN=C(N)N=C(N)Nc1ccc(Cl)cc1)N=C(N)Nc1ccc(Cl)cc1.O=C(O)C(O)C(O)C(O)C(O)CO.O=C(O)C(O)C(O)C(O)C(O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 161
Group description: Upon study enrollment, patients will be bathed with a 2% chlorhexidine gluconate solution on study day 1 and every 48 hours until study completion. The patient will be bathed using standard bathing (non-medicated cloths or soap and water) on study day 2 and every 48 hours after that.

Chlorhexidine gluconate: Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours
Eligibility criteria:
Inclusion Criteria:

Admission to the surgical intensive care unit at The Methodist Hospital (Houston, TX)
Anticipated surgical intensive care unit length of stay of 48 hours or more

Exclusion Criteria:

Pregnancy
Age less than 18 years old
Braden score of less than 9 upon admission to the surgical intensive care unit
Known allergy to chlorhexidine gluconate
Active skin irritation upon admission to the surgical intensive care unit
Intervention: Serelaxin
Trial phase: Phase 2
ATC code: C01DX21
SMILES: CCC(C)C1NC(=O)C(C)NC(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)CNC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(NC(=O)C(NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CO)NC(=O)C(N)CC(=O)O)C(C)C)C(C)CC)CSSCC2NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(CC(N)=O)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C3CCC(=O)N3)CSSCC(NC(=O)CNC(=O)C(C(C)C)NC(=O)C(Cc3cnc[nH]3)NC2=O)C(=O)NC(C(C)O)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(Cc2ccccc2)C(=O)NC(C(=O)O)CSSCC(C(=O)NCC(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CO)C(=O)O)C(C)O)NC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Randomized patients received an intravenous serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min.; duration of infusion depends on time required for completion of magnetic resonance angiography (MRA) data acquisition
Eligibility criteria:
Inclusion Criteria:

Study Parts A and B:

-Cirrhosis of alcohol aetiology according to physician's assessment prior to screening.

Part A:

-Cirrhosis with clinical and/or endoscopic evidence of portal hypertension (e.g. oesophageal varices).

Part B:

Cirrhosis with TIPSS in situ and PPG>5mmHg.
Fully functioning TIPSS without variceal filling as confirmed by portography.

Exclusion Criteria:

Study Parts A and B:

Use of any drug to treat portal hypertension (e.g. vasodilators such as non-selective beta blockers or nitrates) within 1 month prior to screening.
Decompensated cirrhosis (Child-Pugh score >9 points, and/or ascites requiring diuretics, and/or hepatic encephalopathy) at visit 1.
Presence of any non-controlled and clinically significant disease that could affect the study outcome or that would place the patient at undue risk.

Part A:

BMI (weight[kg] / height[m^2]) > 40 kg/m^2.
Any contraindication to having an MRI scan

Part B:

-Contraindication to catheterization
Intervention: Midazolam
Trial phase: Phase 4
ATC code: N05CD08
SMILES: Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 60
Group description: half of the patients will receive Midazolam prior to entering the OR

Midazolam: 1-2.5 mg
Eligibility criteria:
Inclusion Criteria:

Non-diabetic preoperative fasting blood sugar level of 110 mg/dL or less.

Exclusion Criteria:

Fasting blood sugar > than 110mg/dL
Subjects who are pregnant
Subjects who do not speak English
Subjects who are on steroids prior to admission
Hypersensitivity to midazolam
Intervention: Vatiquinone
Trial phase: Phase 1 | Phase 2
SMILES: CC(C)=CCC/C(C)=C/CC/C(C)=C/CC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 20
Group description: Received EPI-743, 15mg/kg up to a maximum dose of 200 mg orally or via gastric tube three times daily with meals. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
Eligibility criteria:
INCLUSION CRITERIA:

Inclusion criteria involve enrollment in protocol 76-HG-0238, Diagnosis and Treatment of Patients with Inborn Errors of Metabolism and Other Genetic Disorders . In addition, patients must:

Be 2-11 years of age
Manifest clinical findings of a neuromuscular disease with a component of impaired energy or oxidation/reduction. Typical symptoms would include hypotonia, dystonia, or seizures.
Have a disorder that is untreatable or poorly treatable.
Have cultured fibroblasts that exhibit reduced viability under conditions of oxidative stress, compared to age matched control fibroblasts.
Have cultured fibroblasts that achieve at least 80% viability rescue with EPI-743 at 1micromolar upon exposure to oxidative stress and that have a half maximal effective concentration of EPI-743 of less than or equal to 50 nanomolar.
Be willing to abstain from initiating the use of dietary supplements and nonprescribed medications, foods or beverages or bars fortified with coenzyme Q(10), vitamin E, super fortified functional foods or beverages, and idebenone.
Be able to travel to the Clinical Center for at least 8 visits.

EXCLUSION CRITERIA:

Age < 2 years or >11 years
Diagnosis of mitochondrial diseases benefiting from treatment and at risk from being moved to placebo
Allergy to EPI-743 or sesame oil
Hepatic insufficiency with liver function tests greater than 3-times the upper limit of normal
Renal insufficiency requiring dialysis
Significant malabsorption of fats precluding drug absorption
Allergy to vitamin E
Significant coagulation abnormalities as evidenced by abnormal PT/PTT tests
Severe end-organ hypo-perfusion syndrome secondary to cardiac failure resulting in lactic acidosis
Ventilator-dependence
Chronic pancreatitis
Clinical history of bleeding requiring ongoing medical management
Abnormal red cell parameters requiring ongoing medical management besides iron supplementation
A platelet disorder
Neutrophils less than 500 mm3
Intervention: SODIUM CHLORIDE
Trial phase: Phase 3
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Infusion of normal saline of equivalent volume to reconstituted zoledronic acid, given only once and run over 2 hours, to occur within 21 days of acute traumatic spinal cord injury.

normal saline 0.9%: Infusion of equivalent volume of 0.9% normal saline to that of the reconstituted zoledronic acid, given only once over two hours, occurring within 21 days of acute traumatic spinal cord injury
Eligibility criteria:
Inclusion Criteria:

Ages 18-65, male or female
Traumatic SCI with Neurological level C4-T10, American Spinal Injury Association (ASIA) Impairment Scale (AIS) A,
Serum calcium level >7.0 mg/dL) at time of study drug administration
Screening baseline serum 25-hydroxy (25-OH) vitamin D of at least 13 ng/ml
No medical contraindication to supplemental vitamin D for participants whose levels are >13 ng/ml but sub-therapeutic (<32ng/ml)
No medical contraindication to supplemental calcium
Weight under 300 pounds, which is the maximum permitted on the dual-energy X-ray absorptiometry (DXA) scanner

Exclusion Criteria:

Ventilator-dependent individuals
Chronic steroid use (defined as >6 months)
Rheumatoid disease with use of prior disease modifying anti-rheumatic drugs (DMARDs) affecting bone density
History of osteoporosis or of treatment for osteopenia or osteoporosis with bisphosphonates, or selective reuptake estrogen modifying agents
Current use of medications* including bisphosphonates to treat osteoporosis (*note that prior calcium or vitamin D use is not an exclusion criteria)
History of more than one lower extremity osteoporosis-related fracture
Chronic renal insufficiency, creatinine clearance < 35 ml/min, during screening
End stage liver or kidney disease
Medical conditions resulting in hypogonadal states that affect bone density
Uncontrolled thyroid disease/thyrotoxicosis
Hereditary or acquired metabolic bone disorder
History of use of unfractionated heparin for >1 year
History of selected antiseizure medications, specifically phenobarbital, phenytoin, carbamazepine, sodium valproate >1 year
Acute or chronic bilateral lower extremity fractures involving tibia or femur, with placement of surgical hardware in any areas of above locations
Severe hypotension requiring use of intravenous blood pressure agents such as dopamine, norepinephrine or phenylephrine. Exception may allow for patients on pressors who arm experiencing hypotension as they acclimate to upright posture.
Inability to provide informed consent and understand the consent process
Facial fractures requiring oral surgery
Dental surgery or oral maxillofacial surgery within 2 weeks of anticipated study drug administration
Pregnancy present on admission
Vitamin D deficiency on admission testing (serum 25-OH D reported as < 13 ng/mL)
Patients with an established reaction to, or history of, anaphylactic shock to aspirin
Intervention: Insulin
Trial phase: Not Applicable
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(N)=O)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)N3CCCC3C(=O)NC(CCCCN)C(=O)NC(C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 60
Group description: Patients randomized to the tight glucose control arm will be placed on an insulin infusion, or continuous low dose insulin drip.

Insulin: Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL
Eligibility criteria:
Inclusion Criteria:

adult patients
diabetic
end stage renal disease undergoing cadaveric renal transplant

Exclusion Criteria:

enrolled in concurrent study to test impact of a drug on graft function after transplant
Intervention: Phorbol 12-myristate 13-acetate
Trial phase: Phase 2
SMILES: CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C(C=C(CO)CC3(O)C(=O)C(C)=CC32)C2C(C)(C)C12OC(C)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Treatment will be initiated within 4.5 hours of awakening, for patients who meet inclusion criteria

IV tPA: IV tPA 0.9 mg/kg maximum of 90 mg. Administered by standard protocol. 10% of the dose by intravenous bolus injection, followed by infusion of the remainder over an hour. Treatment will be initiated within 4.5 hours of awakening with preferred target door to needle time of 60 minutes or less from ED arrival.
Eligibility criteria:
Inclusion Criteria:

Age greater or equal to 18 years, and lower or equal to 80 years.
Signs and symptoms of acute ischemic stroke.
Symptoms present upon awakening.
Arriving to the Emergency Department within 4.5 hours of awakening. Treatment with IV tPA must be initiated prior to 4.5hours from waking up.
NIHSS >3
A non-contrast head CT without hemorrhage and without hypodensity more than 1/3 of the middle cerebral artery (MCA) territory; or MRI demonstrating no hemorrhage, and with a diffusion-weighted imaging (DWI) lesion no greater than 70 mL and FLAIR without a well defined hyperintense lesion that is more than 1/3 of the MCA territory.
Pre-morbid modified Rankin score of 0 or 1.

Exclusion Criteria:

Rapidly improving deficit to an NIHSS less than 3.
Sustained systolic blood pressure greater than 185 mmHg or diastolic blood pressure greater than 110 mmHg despite treatment.
Glucose less than 50 mg/dL.
Stroke or head trauma within last 3 months.
History of intracranial hemorrhage. Symptoms of subarachnoid hemorrhage.
Major surgery within 14 days.
Gastrointestinal (GI)/Genito-urinary (GU) hemorrhage within 21 days.
International normalized ratio (INR) > 1.7.
Heparin within 48 hours with an elevated activated partial thromboplastin time (aPTT).
Platelet count less than 100,000.
Presumed septic embolus or suspicion of bacterial endocarditis.
Suspicion of aortic dissection.
Use of anticoagulants such as dabigatran, rivaroxaban, apixaban, enoxaparin.
Pregnant or lactating women.
Known allergy or sensitivity to tPA.